Factors that could cause actualresults to differ from those discussed in forward-looking statements include,but are not limited to: economic conditions both generally and more specificallyin the markets in which the Company and its banking subsidiary operate;competition for the Company's customers from other providers of financialservices; government legislation and regulation, which change from time to timeand over which the Company has no control; changes in interest rates; materialunforeseen changes in liquidity, results of operations, or financial conditionof the Company's customers; and other risks detailed in the Company's filingswith the Securities and Exchange Commission, all of which are difficult topredict and many of which are beyond the control of the Company S Y Bancorp, Inc. (2) - In September 2008, the Company changed its presentation for disclosing the types of loans in its portfolio to provide more detailed information. Home equity lines of credit were divided into two categories - firstlien and junior lien; however, it was not feasible to obtain comparable amounts for these categories for prior periods. (3) - Amounts not annualizedCertain prior-period amounts have been reclassified to conform with current presentation.S.Y Bancorp, Inc.Nancy B. Davis, 502-625-9176Executive Vice President,Treasurer and Chief Financial OfficerCopyright Business Wire 2009.

With a sputtering offense, the St Louis Cardinals are still in the hunt in the NL Central. The Chicago Cubs have been losing as many games as the Cardinals; no one seems to want to win the division.In their second meeting of interleague play, the Kansas City Royals defeated the Cardinals 7-2 on Friday night.Call it anemic, call it lackluster, call it sputtering. The Cardinals offense still continues to struggle,despite slugger Albert Pujols being inserted back into the lineup.The problem isn't with getting hits. The problem is that the Redbirds get 'em on, get 'em over, but don't get 'em in.For the second straight night, the Cardinals had double-digit runners left on base as they aimlessly try to find a way to manufacture runs against second-tier pitching.This week's Redbird Killer was Gil Meche, who pitched a very solid outing with seven innings while only giving up one run on six hits. Though a very solid pitcher, Meche isn't what I would call a dominating one. The Cardinals just cannot find ways of keeping leads and sustaining offense to take advantage of a weakening NL Central.The Cardinals bullpen was not to blame for the offensive explosion by the Royals, as starter Joel Pineiro gave up seven earned on 10 hits. Despite pitching nearly eight innings, Pineiro didn't have any offensive support.The offense for the Cardinals came from one man, Troy Glaus.

An all but forgotten third basemn, the powerful slugger did manage a 3-for-4 night with a home run and two RBI. A very respectable game, but it was in a losing effort.The Royals offense was led by their own third basemn Alex Gordon. Hitting 2-for-3 with a home run and 4 RBI, the young infielder dashed any hopes of the Cardinals making a comeback.The Royals continue to have the Cardinals number as they have now lost four straight to their interstate rivals. The Redbirds find themselves in a mid-season slump right before the All-Star break. Fortunately for them, they're not the only ones in the division struggling to put together victories.. CAMBRIDGE, Mass.--(Business Wire)--Dyax Corp.

(NASDAQ: DYAX) today announced financial results for the firstquarter ended March 31, 2009 Dyax will host a webcast and conference call at 10a.m. (ET) this morning to review the financial results and corporate progressfor the quarter. Financial ResultsTotal revenues for the first quarter ended March 31, 2009 increased to $6.0million versus $2.6 million for the comparable quarter in 2008. The 2009increase in revenues was primarily due to additional revenue recognized underthe Company`s Licensing and Funded Research Program (LFRP), as well as $1.1million of revenue recognized under a collaboration agreement entered intoduring the second quarter of 2008. Quarterly revenues are expected to fluctuatedue to the timing and amount of future milestone payments, the clinicalactivities of our collaborators and licensees, and the timing and completion ofcontractual commitments. Research and development expenses for the first quarter of 2009 increased to$19.3 million, as compared to $17.1 million for the comparable period in 2008.The 2009 increase in research and development expenses was primarily related tocosts of $5.6 million associated with the manufacture of DX-88 drug substance,the Company`s lead product candidate for the treatment of hereditary angioedema(HAE). Excluding DX-88 manufacturing costs, in the first quarter of 2009,research and development expenses decreased by $3.4 million versus thecomparable period in 2008.

In March 2009, Dyax implemented a workforce reduction to focus its resources onthe commercialization of DX-88 and to support the Company`s long-term financialsuccess. As a result, during the first quarter of 2009, the Company recordedone-time restructuring charges related to the workforce reduction ofapproximately $1.9 million. General and administrative expenses for the first quarter of 2009 increased to$7.8 million, as compared to $5.5 million for the comparable period in 2008. Thehigher general and administrative costs in 2009 were primarily due to increasedinfrastructure to support plans for commercialization of DX-88 for HAE andcharges for share-based compensation expense, as required under Statements ofFinancial Accounting Standards No 123R.